Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 12/20 | 1.00 |
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.72 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17951269 | 0.94 | TLR8 (0.88) | TLR8TLR7NUDT1 | |
| SCHEMBL13999937 | 0.93 | TLR8 (0.86) | TLR8TLR7NUDT1 | |
| SCHEMBL1616206 | 0.91 | TLR8 (0.84) | TLR8TLR7NUDT1 | |
| SCHEMBL15441707 | 0.91 | TLR8 (0.83) | TLR8TLR7NUDT1 | |
| Hydrochloric Acid SCHEMBL6493853 | 0.90 | TLR8 (0.82) | TLR8TLR7NUDT1 | |
| Hydrochloric Acid SCHEMBL3863644 | 0.90 | TLR8 (0.82) | TLR8TLR7NUDT1 | |
| SCHEMBL5113045 | 0.90 | TLR8 (0.82) | TLR8TLR7NUDT1 | |
| SCHEMBL173461 | 0.89 | TLR8 (0.81) | TLR8TLR7NUDT1 | |
| SCHEMBL6105673 | 0.89 | TLR8 (0.81) | TLR8TLR7NUDT1 | |
| SCHEMBL1952956 | 0.89 | TLR8 (0.80) | TLR8TLR7NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067975-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-08 | — | — | US | claimed |
| US-6664265-B2 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | claimed |
| US-20030187016-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-02 | — | — | US | claimed |
| EP-3134402-B1 | 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2020-05-06 | — | — | EP | disclosed |
| US-9447097-B2 | 4-amino-imidazoquinoline compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160222010-A1 | 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-9334268-B2 | 4-amino-imidazoquinoline compounds | HOFFMAN-LA ROCHE INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150299194-A1 | 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-20080306252-A1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306252-A1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306252-A1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20040097542-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-20 | — | — | US | disclosed |
| US-20040072859-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-15 | — | — | US | disclosed |
| US-20040067975-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-08 | — | — | US | disclosed |
| US-6677347-B2 | ANTICARCINOGENIC AND ANTITUMOR AGENTS; VIRICIDED, IMMUNOMODULATORS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-6664265-B2 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | disclosed |
| US-6660735-B2 | Inducing cytokine biosynthesis; viral diseases, neoplastic disorders | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-09 | — | — | US | disclosed |
| US-20030187016-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-02 | — | — | US | disclosed |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | UBS AG, STAMFORD BRANCH | 2003-07-24 | — | — | US | disclosed |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187016-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR8 51/4885TLR7 14/4885NUDT1 792/4885 |
| US-20080306252-A1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | IFNG, IRF3, IL2 | TLR8 50/4885TLR7 24/4885NUDT1 1582/4885 |
| US-20040072859-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR8 273/4885TLR7 84/4885NUDT1 190/4885 |
| US-20160222010-A1 | 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS | TLR4, TLR1, TLR5 | TLR8 9/4885TLR7 4/4885NUDT1 2019/4885 |
| US-20040067975-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR8 51/4885TLR7 14/4885NUDT1 792/4885 |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR8 50/4885TLR7 24/4885NUDT1 1582/4885 |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR8 273/4885TLR7 84/4885NUDT1 190/4885 |
| US-20040097542-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR8 50/4885TLR7 24/4885NUDT1 1582/4885 |
| US-20150299194-A1 | 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS | TLR4, TLR1, TLR5 | TLR8 9/4885TLR7 4/4885NUDT1 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.